Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

About Adamas Pharmaceuticals

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Its ADS-5102 is an extended-release version of amantadine that is intended for once daily administration at bedtime. It is developing ADS-8704, which is a fixed-dose combination of its controlled release version of memantine and donepezil for the treatment of moderate to severe dementia related to Alzheimer's disease. Its ADS 8902, a triple combination antiviral drug therapy for influenza. It also offers Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules (formerly MDX-8704) and Namenda XR (memantine hydrochloride) extended release capsules.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMS
  • CUSIP:
Key Metrics:
  • Previous Close: $17.46
  • 50 Day Moving Average: $15.269
  • 200 Day Moving Average: $15.643
  • 52-Week Range: $12.02 - $31.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.46
  • P/E Growth: -0.070
  • Market Cap: $366.02M
  • Outstanding Shares: 21,929,000
  • Beta: 0.56
Profitability:
  • Net Margins: -3,330.55%
  • Return on Equity: -40.01%
  • Return on Assets: -36.73%
Debt:
  • Current Ratio: 12.73%
  • Quick Ratio: 12.73%
Additional Links:
Companies Related to Adamas Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.13 (94.70% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016MizuhoReiterated RatingBuy$26.00View Rating Details
7/25/2016Credit Suisse Group AGReiterated RatingBuy$21.00View Rating Details
7/22/2016Noble FinancialReiterated RatingBuy$25.00View Rating Details
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00View Rating Details
6/15/2016JMP SecuritiesReiterated RatingBuyView Rating Details
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$44.00View Rating Details
5/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
9/11/2015William BlairReiterated RatingOutperform$35.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
5/10/2016Q1($0.76)($0.65)ViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)ViewN/AView Earnings Details
8/11/2015Q215($0.72)($0.78)ViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)ViewN/AView Earnings Details
3/3/2015$0.64$0.50ViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)ViewN/AView Earnings Details
8/7/2014Q214$0.81$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
Current Year EPS Consensus Estimate: $-3.16 EPS
Next Year EPS Consensus Estimate: $-3.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.88)($0.88)($0.88)
Q4 20161($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Ownership Percentage: 31.79%
Institutional Ownership Percentage: 74.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline
News IconAdamas Pharmaceuticals, Inc. (ADMS) Analyst Review - NewsDen (NASDAQ:ADMS)
newsden.net - September 28 at 8:04 AM
ft.com logo[$$] Despite default worries, China debt attracts brave few (NASDAQ:ADMS)
www.ft.com - September 25 at 8:04 AM
News IconAdamas Pharmaceuticals Inc. (ADMS) Receives “Buy” Rating from ... - NewsDen (NASDAQ:ADMS)
newsden.net - September 24 at 3:17 PM
investornewswire.com logoCan Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Stock Hit Price Target Of $45? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - September 24 at 3:17 PM
globenewswire.com logoAdamas Appoints Michael F. Bigham to Board of Directors - GlobeNewswire (press release) (NASDAQ:ADMS)
globenewswire.com - September 23 at 8:07 AM
publicnow.com logoAdamas Appoints Michael F. Bigham to Board of Directors (NASDAQ:ADMS)
www.publicnow.com - September 23 at 8:07 AM
biz.yahoo.com logoADAMAS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ADMS)
biz.yahoo.com - September 23 at 8:07 AM
publicnow.com logoAllergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease (NASDAQ:ADMS)
www.publicnow.com - September 22 at 8:35 AM
News IconShares Spotted Gapping HIgher Pre-Market: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Post News (NASDAQ:ADMS)
www.kentuckypostnews.com - September 21 at 3:42 PM
rttnews.com logoAdamas Pharmaceuticals Inc. (ADMS) Is Climbing On Phase 3 Study Results - RTT News (NASDAQ:ADMS)
www.rttnews.com - September 21 at 3:42 PM
streetinsider.com logoAdamas Pharma (ADMS) Reports Second ADS-5102 Phase 3 Met Primary Endpoint in PD (NASDAQ:ADMS)
www.streetinsider.com - September 21 at 10:50 AM
zacks.com logoAdamas (ADMS) Parkinson's Disease Drug Positive in Phase III (NASDAQ:ADMS)
www.zacks.com - September 21 at 10:50 AM
schaeffersresearch.com logoBuzz Stocks: Airgain Inc, Microsoft Corporation, and Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
www.schaeffersresearch.com - September 21 at 10:50 AM
rttnews.com logoAdamas Pharmaceuticals Inc. (ADMS) Is Climbing On Phase 3 Study Results (NASDAQ:ADMS)
www.rttnews.com - September 21 at 10:50 AM
finance.yahoo.com logoAdamas Announces Results of EASE LID 3, a Pivotal Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Parkinson’s Disease Patients at the 4th World Parkinson Congress (NASDAQ:ADMS)
finance.yahoo.com - September 21 at 10:50 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Frisco Fastball (NASDAQ:ADMS)
friscofastball.com - September 20 at 3:18 PM
News IconStock Perspective: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Company Earnings Watch - Frisco Fastball (NASDAQ:ADMS)
friscofastball.com - September 18 at 3:18 PM
News IconAdamas Pharmaceuticals Inc Can't Be More Safe. Trades Significantly Higher - Chester News (NASDAQ:ADMS)
www.chesterindependent.com - September 15 at 3:18 PM
News IconAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Short ... - Frisco Fastball (NASDAQ:ADMS)
friscofastball.com - September 14 at 9:42 AM
capitalcube.com logoETF’s with exposure to Adamas Pharmaceuticals, Inc. : September 13, 2016 (NASDAQ:ADMS)
www.capitalcube.com - September 13 at 3:19 PM
publicnow.com logoAdamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 4th World Parkinson Congress (NASDAQ:ADMS)
www.publicnow.com - September 13 at 8:07 AM
finance.yahoo.com logo4:51 pm Adamas Pharmaceuticals announces two data presentations on ADS-5102 for the treatment of Levodopa-induced Dyskinesia (:LID) at the World Parkinson Congress; abstract highlighting data from EASE LID 3 Recognized by WPC as a leading a (NASDAQ:ADMS)
finance.yahoo.com - September 13 at 8:07 AM
globenewswire.com logoAdamas Announces New Employment Inducement Grant Nasdaq ... - GlobeNewswire (press release) (NASDAQ:ADMS)
globenewswire.com - September 10 at 8:04 AM
publicnow.com logoAdamas Announces New Employment Inducement Grant (NASDAQ:ADMS)
www.publicnow.com - September 10 at 8:04 AM
marketexclusive.com logoAllergan PLC (NYSE:AGN) Paves Way For Generic Namzaric To Launch (NASDAQ:ADMS)
marketexclusive.com - September 2 at 3:20 PM
capitalcube.com logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : September 2, 2016 (NASDAQ:ADMS)
www.capitalcube.com - September 2 at 3:20 PM
nasdaq.com logoMid-Day ETF Update: ETFs, Stocks Reverse as Lackluster Manufacturing Data, Crude Slump Weigh on Sentiment (NASDAQ:ADMS)
www.nasdaq.com - September 1 at 3:18 PM
finance.yahoo.com logoAllergan, Adamas Agree to Settle Namzaric Patent Litigation (NASDAQ:ADMS)
finance.yahoo.com - September 1 at 11:45 AM
streetinsider.com logoAllergan (AGN), Adamas Pharma Enter NAMZARIC Patent Suit Settlement with Amneal (NASDAQ:ADMS)
www.streetinsider.com - August 31 at 3:18 PM
rttnews.com logoAllergan, Adamas Announce Settlement With Amneal On NAMZARIC Patent Litigation (NASDAQ:ADMS)
www.rttnews.com - August 31 at 3:18 PM
finance.yahoo.com logoAllergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation (NASDAQ:ADMS)
finance.yahoo.com - August 31 at 8:04 AM
investornewswire.com logoWill Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Hit $45 Price Target? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - August 19 at 3:34 PM
investornewswire.com logoWill Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Surprise This Quarter? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - August 16 at 8:38 PM
finance.yahoo.com logoADAMAS PHARMACEUTICALS INC Financials (NASDAQ:ADMS)
finance.yahoo.com - August 13 at 3:18 PM
capitalcube.com logoETF’s with exposure to Adamas Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:ADMS)
www.capitalcube.com - August 12 at 3:19 PM
capitalcube.com logoAdamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:ADMS)
www.capitalcube.com - August 11 at 12:30 PM
ftsenews.co.uk logoAdamas Pharmaceuticals, Inc. (ADMS) Updated Price Targets ... - FTSE News (NASDAQ:ADMS)
www.ftsenews.co.uk - August 9 at 12:03 PM
twst.com logoAdamas Pharmaceuticals Inc.: Adamas Reports Second Quarter 2016 Financial Results (NASDAQ:ADMS)
www.twst.com - August 4 at 9:01 PM
sg.finance.yahoo.com logoAdamas reports 2Q loss (NASDAQ:ADMS)
sg.finance.yahoo.com - August 4 at 9:01 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Jumps 5.15% on July 29 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 30 at 3:24 PM
investornewswire.com logoCan Shares Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Hit $45? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - July 29 at 3:19 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Drops 6.32% on July 25 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 27 at 11:58 AM
capitalcube.com logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : July 25, 2016 (NASDAQ:ADMS)
www.capitalcube.com - July 25 at 8:21 AM
News IconStock Displaying Signs of a Downtrend: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Press Telegraph (NASDAQ:ADMS)
presstelegraph.com - July 23 at 3:18 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) is Trading Higher on Unusual Volume for July 21 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 23 at 3:18 PM
investornewswire.com logoIs $45 Price Target Attainable For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - July 22 at 3:17 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Jumps 9.66% on July 21 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 21 at 8:53 PM
News IconStock Soars, Rewards Investors Nicely Today: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily (NASDAQ:ADMS)
www.engelwooddaily.com - July 21 at 3:18 PM
News IconStock Marching Up in Session: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - TGP (NASDAQ:ADMS)
telanaganapress.com - July 21 at 3:18 PM
marketexclusive.com logoBiotech Movers: Adamas Pharmaceuticals Inc (NASDAQ:ADMS), Relypsa Inc (NASDAQ:RLYP) and Biogen Inc ... - Market Exclusive (NASDAQ:ADMS)
marketexclusive.com - July 21 at 3:18 PM

Social

Adamas Pharmaceuticals (NASDAQ:ADMS) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff